Highly predictive hologram QSAR models of nitrile-containing cruzain inhibitors

Autor(es)

Silva, Daniel Gedder ^[1] ; Rocha, Josmar Rodrigues ^[1] ; Sartori, Geraldo Rodrigues ^[1] ; Montanari, Carlos Alberto ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Inst Quim Sao Carlos, Grp Quim Med, BR-13566590 Sao Carlos, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS; v. 35, n. 15, p. 3232-3249, 2017.
• Citações Web of Science: 0

Resumo

The HQSAR, molecular docking, and ROCS were applied to a data-set of 57 cruzain inhibitors. The best HQSAR model (q(2) =.70, r(2) =.95, r(test)(2) =.62, q(rand)(2): =.09 and q(rand)(2): =.26), employing well-balanced, diverse training (40) and test (17) sets, was obtained using atoms (A), bonds (B), and hydrogen (H) as fragment distinctions and 6-9 as fragment sizes. This model was then used to predict the unknown potencies of 121 compounds (the V1 database), giving rise to a satisfactory predictive r(2) value of .65 (external validation). By employing an extra external data-set comprising 1223 compounds (the V3 database) either retrieved from the ChEMBL or CDD databases, an overall ROC AUC score well over .70 was obtained. The contribution maps obtained with the best HQSAR model (model 3.4) are in agreement with the predicted binding mode and with the biological potencies of the studied compounds. We also screened these compounds using the ROCS method, a Gaussian-shape volume filter able to identify quickly the shapes that match a query molecule. The area under the curve (AUC) obtained with the ROC curves (ROC AUC) was .72, indicating that the method was very efficient in distinguishing between active and inactive cruzain inhibitors. These set of information guided us to propose novel cruzain inhibitors to be synthesized. Then, the best HQSAR model obtained was used to predict the pIC(50) values of these new compounds. Some compounds identified using this method have shown calculated potencies higher than those which have originated them. (AU)

• Processo FAPESP: 13/18009-4 - Planejamento, síntese e atividade tripanossomicida de inibidores covalentes reversíveis da enzima cruzaína
• Beneficiário: Carlos Alberto Montanari
• Linha de fomento: Auxílio à Pesquisa - Temático
• Processo FAPESP: 13/01128-0 - Planejamento e síntese de inibidores covalentes reversíveis da enzima cruzaína
• Beneficiário: Daniel Gedder Silva
• Linha de fomento: Bolsas no Brasil - Doutorado
• Processo FAPESP: 16/10362-5 - Síntese de dipeptidil nitrilas como inibidores de cruzaína para realização de modificações no warhead
• Beneficiário: Daniel Gedder Silva
• Linha de fomento: Bolsas no Exterior - Estágio de Pesquisa - Doutorado